HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Daunorubicin continuous infusion induces more toxicity than bolus infusion in acute lymphoblastic leukemia induction regimen: a randomized study.

Abstract
We report the first randomized study assessing the efficacy and safety of daunorubicin (DNR) continuous infusion (CI) compared to the more conventional 30-min infusion (i.v.) in newly diagnosed adult acute lymphoblastic leukemia (ALL). Seventy-seven patients were initially randomized to receive either a 24-h CI DNR (60 mg/m2 days 2-4) (40 patients) or bolus DNR at the same dosage (37 patients) with vincristine (2 mg i.v. days 1, 8, 15) and oral prednisone (60 mg/m2 days 1-15), without hematopoietic growth factor support, as an induction regimen. The distribution of adverse prognostic factors was comparable in the two-induction arm. Acute toxicity was more important in the CI arm. Gram negative infection (9 vs 1 gram negative septicemia, P = 0.01) and infection-related deaths (6 vs 1 deaths, P = NS) occurred more frequently in the CI arm during the induction treatment than in the i.v. arm, leading to the study interruption. Neutropenia but not thrombopenia duration was significantly longer in the CI arm than in the i.v. arm (18 days vs 14 days, P > 0.05 and 16 days vs 12 days, P > 0.05, respectively). Despite a similar CR rate according to the method of DNR administration (68% in the CI DNR arm vs 76% in the i.v. arm after the first course), there was a trend toward higher freedom from relapse (FFR) after DNR CI (48% vs 28% in the i.v. arm at 5 years, P = NS), suggesting that despite this high toxicity, DNR CI may improve the CR quality and decrease further the residual disease.
AuthorsM Hunault-Berger, N Milpied, M Bernard, J P Jouet, M Delain, B Desablens, A Sadoun, F Guilhot, P Casassus, N Ifrah
JournalLeukemia (Leukemia) Vol. 15 Issue 6 Pg. 898-902 (Jun 2001) ISSN: 0887-6924 [Print] England
PMID11417474 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)
Chemical References
  • Antibiotics, Antineoplastic
  • Cytarabine
  • Vincristine
  • Etoposide
  • Cyclophosphamide
  • Asparaginase
  • Carmustine
  • Prednisone
  • Methotrexate
  • Daunorubicin
Topics
  • Adolescent
  • Adult
  • Aged
  • Antibiotics, Antineoplastic (administration & dosage, adverse effects)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
  • Asparaginase (administration & dosage)
  • Bone Marrow Transplantation
  • Carmustine (administration & dosage)
  • Combined Modality Therapy
  • Cyclophosphamide (administration & dosage)
  • Cytarabine (administration & dosage)
  • Daunorubicin (administration & dosage, adverse effects)
  • Etoposide (administration & dosage)
  • Female
  • Gram-Negative Bacterial Infections (etiology)
  • Humans
  • Immunocompromised Host
  • Infusions, Intravenous
  • Injections, Intravenous
  • Life Tables
  • Male
  • Methotrexate (administration & dosage)
  • Middle Aged
  • Neutropenia (chemically induced)
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, mortality, therapy)
  • Prednisone (administration & dosage)
  • Remission Induction
  • Survival Analysis
  • Thrombocytopenia (chemically induced)
  • Treatment Outcome
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: